Connect with us
neuralink link device with white background neuralink link device with white background

News

Neuralink still recruiting patients for its clinical trials: The PRIME Study

(Credit: Neuralink)

Published

on

Neuralink is still recruiting patients for its human clinical trials, The PRIME Study. PRIME stands for Precise Robotically Implanted Brain-Computer Interface. Neurlink’s prime study will test the company’s brain-computer interface (BCI) by evaluating the company’s N1 implant and R1 surgical robot. 

The R1 surgical robot enables Neurlink to place its N1 implant into the region of the brain that controls movement. The surgical placement of N1 is delicate since the implant contains ultra-fine, flexible threads. Neuralink’s N1 implant should enable people with paralysis to control external devices, like cellphones or computers, with their thoughts.

Below are the qualifications Neuralink has for patients who wish to enroll in its PRIME Study. 

  • Persons that have quadriplegia (limited function in all 4 limbs) due to spinal cord injury or amyotrophic lateral sclerosis (ALS) and are at least 1-year post-injury (without improvement) 
  • Participants must be at least 22 years old. 
  • Participants must have a consistent and reliable caregiver.

Neuralink cannot accept the following individuals for the PRIME Study: 

  • Patients with an active implanted device (pacemaker, deep brain stimulator (DBS), etc.) 
  • Individuals who have a history of seizures 
  • Persons who require MRIs for an ongoing medical condition 
  • Persons who are receiving transcranial magnetic

The PRIME Study will last approximately 6 years, so individuals who wish to participate in Neuralink’s human clinical trials must be prepared for a long-term commitment. The trial is split into two parts. The Primary Study will take approximately 18 months, consisting of 9 at-home and in-person clinic visits. Neuralink PRIME Study patients must be prepared to participate in 1-hour BCI research sessions at least 2 times per week. 

After the 18-month Primary Study, Nueralink patients will enter the long-term follow-up phase of the human clinical trials. This phase lasts over 5 years, consisting of a total of 20 visits. 

Advertisement

The Teslarati team would appreciate hearing from you. If you have any tips, contact me at maria@teslarati.com or via X @Writer_01001101.

Maria--aka "M"-- is an experienced writer and book editor. She's written about several topics including health, tech, and politics. As a book editor, she's worked with authors who write Sci-Fi, Romance, and Dark Fantasy. M loves hearing from TESLARATI readers. If you have any tips or article ideas, contact her at maria@teslarati.com or via X, @Writer_01001101.

Advertisement
Comments

Elon Musk

Tesla Q1 Earnings: What Elon Musk and Co. will answer during the call

Published

on

Credit: Tesla

Tesla (NASDAQ: TSLA) is set to hold its Earnings Call for the first quarter of 2026 on Wednesday, and there are a lot of interesting things that are swirling around in terms of speculation from investors.

With the company’s executives, including CEO Elon Musk, answering a handful of questions that investors submit through the Say platform, fans want to know a lot of things about a lot of things.

These five questions come from Retail Investors, who are normal, everyday shareholders:

  1. When will we have the Optimus v3 reveal? When will Optimus production start, since we ended the Model S and Model X production earlier than mid-year? What’s the expected Optimus production rate exiting this year? What are the initial targeted skills?
  2. What milestones are you targeting for unsupervised FSD and Robotaxi expansion beyond Austin this year, and how will that drive recurring revenue?
  3. How will Hardware 3 cars reach Unsupervised Full Self-Driving?
  4. When do you expect Unsupervised Full Self-Driving to reach customer cars?
  5. When will Robotaxi expand past its current limited rollout?

Additionally, these are currently the three questions that are slated to be answered by Institutional Firms, which also answer a handful of questions during the call:

  1. Now that FSD has been approved in the Netherlands and is expected to launch across Europe this summer, can you discuss your Robotaxi strategy for the region?
  2. What enabled you to finish the AI5 tapeout early and were there any changes to the original vision? Last week, Elon said AI5 will go into Optimus and the Supercomputer, but one month ago said it would go into the Robotaxi. Has AI5 been dropped from the vehicle roadmap?
  3. Given the recent NHTSA incident filings, can you update us on the Robotaxi safety data? If safety validation remains the primary bottleneck, why not deploy thousands of vehicles to accelerate the removal of the safety driver?

The questions range through every current Tesla project, including FSD expansion and Optimus. However, many of the answers we will get will likely be repetitive answers we’ve heard in the past.

This is especially pertinent when the questions about when Unsupervised FSD will reach customer cars: we know Musk will say that it will happen this year. Is Tesla capable of that? Maybe. But a more transparent answer that is more revealing of a true timeline would be appreciated.

Hardware 3 owners are anxiously awaiting the arrival of FSD v14 Lite, which was promised to them last year for a release sometime this year.

The Earnings Call is set to take place on Wednesday at market close.

Continue Reading

Elon Musk

Elon Musk reveals shocking Tesla Optimus patent detail

What looked promising on paper and in simulations failed to deliver the reliability required for a robot expected to handle delicate tasks like folding laundry, assembling electronics, or assisting in factories and homes.

Published

on

Credit: Tesla

Elon Musk revealed a shocking detail on the Tesla Optimus patent that was revealed last week. Despite it being made public for the first time, Musk said the company has already moved on from the design, an incredible truth about the development of new technology: things move fast.

Musk dropped a bombshell about the Tesla Optimus humanoid robot hand patent that was released last week. Musk, candidly replying to a post late at night on X, revealed that what is a new technology to many fans and insiders is actually old news to those developing the tech directly.

“We already changed the design,” Musk said. “This one didn’t actually work.”

Patents, after all, are often viewed as blueprints for future products. Yet Musk revealed that the rolling contact mechanism—intended to provide smooth, low-friction articulation in the fingers—had already been scrapped after real-world testing exposed its shortcomings.

What looked promising on paper and in simulations failed to deliver the reliability required for a robot expected to handle delicate tasks like folding laundry, assembling electronics, or assisting in factories and homes.

The hand has been one of the biggest challenges for Tesla engineers since Optimus development started years ago. Musk has said that there is not enough recognition for how incredible and useful the human hand is, and designing one for a humanoid robot has been the biggest challenge of all.

Tesla is stumped on how to engineer this Optimus part, but they’re close

This moment underscores the persistent engineering hurdles in achieving reliable humanoid hand dexterity. Human fingers are marvels of evolution: 27 bones, intricate tendons, ligaments, and a network of sensors working in perfect harmony. Replicating that in metal and silicon is extraordinarily difficult.

Rolling contacts promised reduced wear and precise motion, but testing likely revealed issues with durability under repeated stress, grip stability on varied surfaces, or the micro-precision needed for fine motor skills.

These aren’t minor tweaks, but instead they represent fundamental challenges that have plagued robotics teams for decades. Even advanced competitors struggle here—hands remain the Achilles’ heel of most humanoids because the margin for error is razor-thin.

A fraction of a millimeter off, and a robot drops a glass or fails to button a shirt.

What makes Musk’s reply remarkable is how it signals Tesla’s direct communication style on prototype limitations. While many companies guard failures behind glossy marketing and vague timelines, Tesla openly shares setbacks.

Musk was forthcoming about the failure of this recent design. This transparency builds trust with investors, engineers, and fans. It shows Tesla treats Optimus development like true science: rapid iteration, rigorous testing, and zero tolerance for hype that doesn’t match reality.

The disclosure from Musk also highlights Tesla’s blistering pace of development. By the time the patents are published, which is often over a year after the initial filing, the technology has already evolved.

Optimus is far from a static product, and it’s a living project advancing weekly.

In the high-stakes race for general-purpose robots, Tesla’s approach stands out. Admitting a finger-joint design “didn’t actually work” isn’t a weakness—it’s confidence.

True innovation demands confronting failure head-on, and Musk just reminded the world that Optimus is being engineered that way. The next version of those hands is already in testing, and it will be better because Tesla isn’t afraid to say what didn’t work.

Continue Reading

Elon Musk

Tesla is sending its humanoid Optimus robot to the Boston Marathon

Tesla’s Optimus robot is heading to the Boston Marathon finish line

Published

on

By

Tesla’s Optimus humanoid robot will be stationed at the Tesla showroom at 888 Boylston Street in Boston, right along the final stretch of the Boston Marathon today, ready to cheer on runners and pose for photos with spectators.

According to a Tesla email shared by content creator Sawyer Merritt on X, Optimus will be at the Boston Boylston Street showroom on April 20, coinciding with Marathon Monday weekend. The Boston Marathon finishes on Boylston Street, and the surrounding area draws hundreds of thousands of spectators along with international broadcast coverage. Placing Optimus there puts it in front of a massive public audience at zero advertising cost.

The Tesla showroom is at 888 Boylston Street, between Gloucester Street and Fairfield Street. The final mile of the marathon runs directly along Boylston Street, with runners passing the big stores before reaching the finish line at Copley Square.

Optimus was first announced at Tesla’s AI Day event on August 19, 2021, when Elon Musk presented a vision for a general-purpose robot designed to take on dangerous, repetitive, and unwanted tasks. In March 2026, Optimus appeared at the Appliance and Electronics World Expo in Shanghai, where on-site staff stated that mass production of the robot could begin by the end of 2026. Before that, it showed up at the Tesla Hollywood Diner opening in July 2025 and at a Miami showroom event in December 2025.

Tesla’s well-calculated display of Optimus gives the public a low-pressure first encounter with a robot that Tesla is preparing  to soon deploy at scale. The company has previously indicated plans to manufacture Optimus robots at its Fremont facility at up to 1 million units annually, with an Optimus production line at Gigafactory Texas targeting 10 million units per year.

Tesla showcases Optimus humanoid robot at AWE 2026 in Shanghai

Musk has said that Optimus “has the potential to be more significant than the vehicle business over time,” and separately that roughly 80 percent of Tesla’s future value will come from the robot program. Whether that holds depends on production execution. For now, Boston gets a preview of what that future looks like, standing at the finish line on Boylston Street while 32,000 runners pass by.

Continue Reading